Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. METHODS: We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascul...

Descripción completa

Detalles Bibliográficos
Autor principal: Antithrombotic Trialists' (ATT) Collaboration
Formato: Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2009
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715005/
https://www.ncbi.nlm.nih.gov/pubmed/19482214
http://dx.doi.org/10.1016/S0140-6736(09)60503-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715005/
https://www.ncbi.nlm.nih.gov/pubmed/19482214
http://dx.doi.org/10.1016/S0140-6736(09)60503-1

Ejemplares similares